Self-amplifying nicotinamide N-methyltransferase feedback loops: Drivers of anticancer drug resistance and therapeutic opportunities

Shuang-Zhou Bi; Xiang-Li Ni; Wei-Dong Sun; Chen-Ying Zhang; An Liu; Shi-Yan Lai; Jiang-Hua Li

doi:10.1016/j.jpha.2026.101588

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2026 > Accepted Manu

Shuang-Zhou Bi, Xiang-Li Ni, Wei-Dong Sun, Chen-Ying Zhang, An Liu, Shi-Yan Lai, Jiang-Hua Li. Self-amplifying nicotinamide N-methyltransferase feedback loops: Drivers of anticancer drug resistance and therapeutic opportunities[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101588

Citation:

Shuang-Zhou Bi, Xiang-Li Ni, Wei-Dong Sun, Chen-Ying Zhang, An Liu, Shi-Yan Lai, Jiang-Hua Li. Self-amplifying nicotinamide N-methyltransferase feedback loops: Drivers of anticancer drug resistance and therapeutic opportunities[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101588

Citation:

Shuang-Zhou Bi, Xiang-Li Ni, Wei-Dong Sun, Chen-Ying Zhang, An Liu, Shi-Yan Lai, Jiang-Hua Li. Self-amplifying nicotinamide N-methyltransferase feedback loops: Drivers of anticancer drug resistance and therapeutic opportunities[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101588

PDF( 7572 KB)

Self-amplifying nicotinamide N-methyltransferase feedback loops: Drivers of anticancer drug resistance and therapeutic opportunities

doi: 10.1016/j.jpha.2026.101588

Physical Education College, Jiangxi Normal University, Nanchang, 330022, China

Funds:

This work was supported by the National Natural Science Foundation of China (Grant No.: 32260014), Social Science Planning Project of Jiangxi Province, China (Grant No.: 19WT94), and the Graduate Innovation Fund Project of Education Department of Jiangxi Province, China (Grant No.: YC2025-B067).

Received Date: Aug. 19, 2025
Accepted Date: Feb. 14, 2026
Rev Recd Date: Feb. 14, 2026
Available Online: Feb. 28, 2026

Abstract

Abstract

Drug resistance poses a significant challenge in cancer therapy, undermining treatment efficacy and patient survival. Nicotinamide N-methyltransferase (NNMT), a pivotal cytoplasmic enzyme, plays a crucial role in mediating drug resistance by linking nicotinamide adenine dinucleotide (oxidized form) (NAD⁺) metabolism and the S-adenosylmethionine/S-adenosylhomocysteine (SAM/SAH) methylation cycle. Notably, self-amplifying NNMT feedback loops in cancer cells drive the development of resistance to anticancer drugs. NNMT reduces the cytotoxicity of chemotherapeutic agents, drives resistance to targeted therapies such as kinase inhibitors and monoclonal antibodies, and facilitates immune evasion, thereby diminishing the efficacy of immunotherapy. It also amplifies resistance through self-reinforcing feedback loops, including the NNMT/aldehyde dehydrogenase 3 family member A1 (ALDH3A1)/lactate/NNMT and early growth response 1 (EGR1)/NNMT/EGR1 circuits, which intensify resistance signaling within the tumor microenvironment. While novel therapeutic strategies targeting NNMT, such as gene silencing, small-molecule inhibitors, and feedback circuit interventions, show promise in reversing resistance, their clinical translation remains challenging. Future research should focus on elucidating the interplay between NNMT and lactate metabolism (including exercise-modulated lactylation), identifying additional NNMT-associated feedback loops, and investigating NNMT's regulatory roles in alternative metabolic pathways. These efforts may yield new insights and therapeutic targets to overcome drug resistance and improve clinical outcomes for cancer patients.
- Nicotinamide N-methyltransferase,
- Drug resistance,
- Feedback loops,
- Lactate metabolism,
- Therapeutic targeting

FullText(HTML)

References(115)

References

[1]	J. Remon, C.E. Steuer, S.S. Ramalingam, et al., Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients, Ann. Oncol. 29 (2018) i20-i27.
[2]	A.B. Sarmento-Ribeiro, A. Scorilas, A.C. Goncalves, et al., The emergence of drug resistance to targeted cancer therapies: Clinical evidence, Drug Resist. Updat. 47 (2019), 100646.
[3]	N. Vasan, J. Baselga, D.M. Hyman, A view on drug resistance in cancer, Nature 575 (2019) 299-309.
[4]	M.L. De Angelis, F. Francescangeli, F. La Torre, et al., Stem cell plasticity and dormancy in the development of cancer therapy resistance, Front. Oncol. 9 (2019), 626.
[5]	K. Bukowski, M. Kciuk, R. Kontek, Mechanisms of multidrug resistance in cancer chemotherapy, Int. J. Mol. Sci. 21 (2020), 3233.
[6]	J Li, W Sun, X Zhu, et al., Nicotinamide N-methyltransferase (NNMT): A new hope for treating aging and age-related conditions, Metabolites 14 (2024), 343.
[7]	S Bi, W Sun, X Zhu, et al., Nicotinamide N-methyltransferase in cardiovascular diseases: Mechanistic insights and therapeutic potential, Eur. J. Med. Chem. 295 (2025), 117790.
[8]	M. Komatsu, T. Kanda, H. Urai, et al., NNMT activation can contribute to the development of fatty liver disease by modulating the NAD+ metabolism, Sci. Rep. 8 (2018), 8637.
[9]	D. Kraus, Q Yang, D Kong, et al., Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity, Nature 508 (2014) 258-262.
[10]	D. Sartini, A. Santarelli, V. Rossi, et al., Nicotinamide N-methyltransferase upregulation inversely correlates with lymph node metastasis in oral squamous cell carcinoma, Mol. Med. 13 (2007) 415-421.
[11]	M. Yao, H. Tabuchi, Y. Nagashima, et al., Gene expression analysis of renal carcinoma: Adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma, J. Pathol. 205 (2005) 377-387.
[12]	Y. Wu, M.S. Siadaty, M.E. Berens, et al., Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration, Oncogene 27 (2008) 6679-6689.
[13]	J.S.J. Jang, H.Y. Cho, Y.J. Lee, et al., The differential proteome profile of stomach cancer: Identification of the biomarker candidates, Oncol. Res. Featur. Preclin. Clin. Cancer Ther. 14 (2004) 491-499.
[14]	M. Roessler, W. Rollinger, S. Palme, et al., Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer, Clin. Cancer Res. 11 (2005) 6550-6557.
[15]	W Sun, X Zhu, J Li, et al., Nicotinamide N-methyltransferase (NNMT): A novel therapeutic target for metabolic syndrome, Front. Pharmacol. 15 (2024), 1410479.
[16]	R.B. Parsons, P.D. Facey, Nicotinamide N-methyltransferase: An emerging protagonist in cancer macro(r)evolution, Biomolecules 11 (2021), 1418.
[17]	A. Roberti, A.F. Fernandez, M.F. Fraga, Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation, Mol. Metab. 45 (2021), 101165.
[18]	W Wang, C Yang, T Wang, et al., Complex roles of nicotinamide N-methyltransferase in cancer progression, Cell Death Dis. 13 (2022), 267.
[19]	X Li, Y Pi, Y Chen, et al., Nicotinamide N-methyltransferase: A promising biomarker and target for human cancer therapy, Front. Oncol. 12 (2022), 894744.
[20]	L. Togni, M. Mascitti, D. Sartini, et al., Nicotinamide N-methyltransferase in head and neck tumors: A comprehensive review, Biomolecules 11 (2021), 1594.
[21]	Y.C. Hsu, H.Y. Chen, S. Yuan, et al., Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity, BMC Med. 11 (2013), 106.
[22]	T Yu, Y Wang, P Chen, et al., Effects of nicotinamide N-methyltransferase on PANC-1 cells proliferation, metastatic potential and survival under metabolic stress, Cell. Physiol. Biochem. 35 (2015) 710-721.
[23]	Y Cui, D Yang, W Wang, et al., Nicotinamide N-methyltransferase decreases 5-fluorouracil sensitivity in human esophageal squamous cell carcinoma through metabolic reprogramming and promoting the warburg effect, Mol. Carcinog. 59 (2020) 940-954.
[24]	Y. Wang, J. Zeng, W. Wu, et al., Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization, Breast Cancer Res. 21 (2019), 64.
[25]	J. Heide, A.J. Bilecz, S. Patnaik, et al., NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity, Nature 645 (2025) 1051-1059.
[26]	J Wang, X Liu, Y Huang, et al., Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells, Cell Death Discov. 8 (2022), 170.
[27]	F.P. D’Andrea, A. Safwat, M. Kassem, et al., Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance, Radiother. Oncol. 99 (2011) 373-378.
[28]	B Wang, T Wu, NNMT suppresses H3K9me3 to facilitate malignant progression and drug resistance in gastric cancer, Arab J. Gastroenterol. 26 (2025) 104-111.
[29]	J. Dai, X. Lu, C. Zhang, et al., NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer, Mol. Cancer 24 (2025), 79.
[30]	M Yang, B Wang, W Hou, et al., NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer, J. ImmunoTherapy Cancer 12 (2024), e009281.
[31]	H.K. Choi, K.B. Cho, N.T.T. Phuong, et al., SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells, Mol. Pharmaceutics 10 (2013) 2517-2527.
[32]	X Yang, S Li, C Xu, et al., Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma, Cancer Biol. Ther. 25 (2024), 2365449.
[33]	X Xie, H Liu, Y Wang, et al., Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway, Oncotarget 7 (2016) 45837-45848.
[34]	Y Niu, M Xiang, W Yang, et al., NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer, World J. Gastroenterol. 31 (2025), 100785.
[35]	Y Wei, Y Guo, J Zhou, et al., Nicotinamide overcomes doxorubicin resistance of breast cancer cells through deregulating SIRT1/Akt pathway, Anti Cancer Agents Med. Chem. 19 (2019) 687-696.
[36]	B. Ghezzi, I. Fiorilla, A. Carreira, et al., NAMPT and NNMT released via extracellular vesicles and as soluble mediators are distinguished traits of BRAF inhibitor resistance of melanoma cells impacting on the tumor microenvironment, Cell Commun. Signal. 23 (2025), 348.
[37]	Z. Hou, Z. Wang, F. Yang, et al., Nicotinamide N-methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling, Mol. Oncol. 2025. https://doi.org/10.1002/1878-0261.70097.
[38]	D.H. Bach, D. Kim, S Bae, et al., Targeting nicotinamide N-methyltransferase and miR-449a in EGFR-TKI-resistant non-small-cell lung cancer cells, Mol. Ther. Nucleic Acids 11 (2018) 455-467.
[39]	Y Piao, J Liang, L. Holmes, et al., Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition, Clin. Cancer Res. 19 (2013) 4392-4403.
[40]	J. Kanska, P.P. Aspuria, B. Taylor-Harding, et al., Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT, Oncotarget 8 (2017) 26200-26220.
[41]	J Li, S You, S Zhang, et al., Elevated N-methyltransferase expression induced by hepatic stellate cells contributes to the metastasis of hepatocellular carcinoma via regulation of the CD44v3 isoform, Mol. Oncol. 13 (2019) 1993-2009.
[42]	Y Xie, J Liu, H Jiang, et al., Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance Hedgehog signaling activity and drug resistance in multiple myeloma, Oncogene 39 (2020) 922-934.
[43]	C Wu, Y Liu, W Liu, et al., NNMT-DNMT1 axis is essential for maintaining cancer cell sensitivity to oxidative phosphorylation inhibition, Adv. Sci. 10 (2023), 2202642.
[44]	T. Haider, V. Pandey, N. Banjare, et al., Drug resistance in cancer: Mechanisms and tackling strategies, Pharmacol. Rep. 72 (2020) 1125-1151.
[45]	M. Nakajima, H. Kato, Treatment options for esophageal squamous cell carcinoma, Expert Opin. Pharmacother. 14 (2013) 1345-1354.
[46]	D. Hanahan, R.A. Weinberg, Hallmarks of cancer: The next generation, Cell 144 (2011) 646-674.
[47]	M.V. Liberti, J.W. Locasale, The Warburg effect: How does it benefit cancer cells Trends Biochem. Sci. 41 (2016) 211-218.
[48]	J.R. Cantor, D.M. Sabatini, Cancer cell metabolism: one hallmark, many faces, Cancer Discov. 2 (2012) 881-898.
[49]	M. Bockwoldt, D. Houry, M. Niere, et al., Identification of evolutionary and kinetic drivers of NAD-dependent signaling, Proc. Natl. Acad. Sci. U S A 116 (2019) 15957-15966.
[50]	N Xie, L Zhang, W Gao, et al., NAD+ metabolism: Pathophysiologic mechanisms and therapeutic potential, Signal Transduct. Target. Ther. 5 (2020), 227.
[51]	W Sun, X Zhu, J Li, et al., Nicotinamide N-methyltransferase (NNMT): A key enzyme in cancer metabolism and therapeutic target, Int. Immunopharmacol. 142 (2024), 113208.
[52]	S. Reed, D. Quelle, p53 acetylation: Regulation and consequences, Cancers 7 (2015) 30-69.
[53]	M.A. de la Cruz-Morcillo, M.L.L. Valero, J.L. Callejas-Valera, et al., Retraction Note: P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: Implication in resistance, Oncogene 43 (2024), 1232.
[54]	A.S. Alzahrani, PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside, Semin. Cancer Biol. 59 (2019) 125-132.
[55]	S. Dong, S. Liang, Z. Cheng, et al., ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer, J. Exp. Clin. Cancer Res. 41 (2022), 15.
[56]	A.J. Abadi, A. Zarrabi, M.H. Gholami, et al., Small in size, but large in action: microRNAs as potential modulators of PTEN in breast and lung cancers, Biomolecules 11 (2021), 304.
[57]	M. Ashrafizadeh, M. Najafi, H Ang, et al., PTEN, a barrier for proliferation and metastasis of gastric cancer cells: From molecular pathways to targeting and regulation, Biomedicines 8 (2020), 264.
[58]	R. Perez-Tomas, Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment, Curr. Med. Chem. 13 (2006) 1859-1876.
[59]	A. Sparreboom, R. Danesi, Y. Ando, et al., Pharmacogenomics of ABC transporters and its role in cancer chemotherapy, Drug Resist. Updat. 6 (2003) 71-84.
[60]	M.T. Kuo, Roles of multidrug resistance genes in breast cancer chemoresistance. Breast Cancer Chemosensitivity. Adv. Exp. Med. Biol. 608 (2007) 23-30.
[61]	S. Labialle, L. Gayet, E. Marthinet, et al., Transcriptional regulators of the human multidrug resistance 1 gene: Recent views, Biochem. Pharmacol. 64 (2002) 943-948.
[62]	D.H. Lee, Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures, Pharmacol. Ther. 174 (2017) 1-21.
[63]	M. Apicella, E. Giannoni, S. Fiore, et al., Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies, Cell Metab. 28 (2018) 848-865.e6.
[64]	H. Makinoshima, M. Takita, S. Matsumoto, et al., Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma, J. Biol. Chem. 289 (2014) 20813-20823.
[65]	W Li, C Zhou, L Yu, et al., Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer, Autophagy 20 (2024) 114-130.
[66]	S. Di Biase, H.S. Shim, K.H. Kim, et al., Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy, PLoS Biol. 15 (2017), e2001951.
[67]	Y Liu, S. Kimpara, N.M. Hoang, et al., EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma, Blood 142 (2023) 1879-1894.
[68]	V. Audrito, A. Manago, S. La Vecchia, et al., Nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic target in BRAF-mutated metastatic melanoma, JNCI J. Natl. Cancer Inst. 110 (2018) 290-303.
[69]	T.T. Batchelor, A.G. Sorensen, E. di Tomaso, et al., AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, Cancer Cell 11 (2007) 83-95.
[70]	E.C. Quant, A.D. Norden, J. Drappatz, et al., Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab, Neuro Oncol. 11 (2009) 550-555.
[71]	M.C. Chamberlain, Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence, Neurology 72 (2009) 772-774.
[72]	B.J. Scott, E.C. Quant, M.B. McNamara, et al., Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors, Neuro Oncol. 12 (2010) 603-607.
[73]	O.A. Ulanovskaya, A.M. Zuhl, B.F. Cravatt, NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink, Nat. Chem. Biol. 9 (2013) 300-306.
[74]	A. Moustakas, C.H. Heldin, Induction of epithelial-mesenchymal transition by transforming growth factor β, Semin. Cancer Biol. 22 (2012) 446-454.
[75]	C.T. Wallington-Beddoe, M. Sobieraj-Teague, B.J. Kuss, et al., Resistance to proteasome inhibitors and other targeted therapies in myeloma, Br. J. Haematol. 182 (2018) 11-28.
[76]	P. Robak, I. Drozdz, J. Szemraj, et al., Drug resistance in multiple myeloma, Cancer Treat. Rev. 70 (2018) 199-208.
[77]	L. Armas-Lopez, J. Zuniga, O. Arrieta, et al., The Hedgehog-GLI pathway in embryonic development and cancer: Implications for pulmonary oncology therapy, Oncotarget 8 (2017) 60684-60703.
[78]	Z Zhao, Y Mei, Z Wang, et al., The effect of oxidative phosphorylation on cancer drug resistance, Cancers 15 (2023), 62.
[79]	K.M. Lee, J.M. Giltnane, J.M. Balko, et al., MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation, Cell Metab. 26 (2017) 633-647.e7.
[80]	O. Cadassou, L.P. Jordheim, OXPHOS inhibitors, metabolism and targeted therapies in cancer, Biochem. Pharmacol. 211 (2023), 115531.
[81]	B.J. Peters, E. van Geffen, D. Hilarius, et al., The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell Lung cancer, Lung Cancer 206 (2025), 108642.
[82]	K.C. Ohaegbulam, A. Assal, E. Lazar-Molnar, et al., Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway, Trends Mol. Med. 21 (2015) 24-33.
[83]	T. Powles, L. Morrison, Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma, Nat. Rev. Urol. 15 (2018) 585-587.
[84]	Y Jiang, Y Wang, G Chen, et al., Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer, Cell Metab. 36 (2024) 1806-1822.e11.
[85]	H Lv, G Lv, C Chen, et al., NAD+ metabolism maintains inducible PD-L1 expression to drive tumor immune evasion, Cell Metab. 33 (2021) 110-127.e5.
[86]	S. Hiratsuka, A. Watanabe, Y. Sakurai, et al., The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase, Nat. Cell Biol. 10 (2008) 1349-1355.
[87]	M.K. Kilgour, S. MacPherson, L.G. Zacharias, et al., 1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer, Sci. Adv. 7 (2021), eabe1174.
[88]	H Yao, X Chen, T Wang, et al., A MYC-controlled redox switch protects B lymphoma cells from EGR1-dependent apoptosis, Cell Rep. 42 (2023), 112961.
[89]	H.Q. Duong, K. You, S. Oh, et al., Silencing of NRF2 reduces the expression of ALDH1A1 and ALDH3A1 and sensitizes to 5-FU in pancreatic cancer cells, Antioxidants 6 (2017), 52.
[90]	Y Chen, H Yan, L Yan, et al., Hypoxia-induced ALDH3A1 promotes the proliferation of non-small-cell lung cancer by regulating energy metabolism reprogramming, Cell Death Dis. 14 (2023), 617.
[91]	B. Parajuli, M.L. Fishel, T.D. Hurley, Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells, J. Med. Chem. 57 (2014) 449-461.
[92]	H. Zhang, G. Zhang, M. Xiao, et al., Two-polarized roles of transcription factor FOSB in lung cancer progression and prognosis: Dependent on p53 status, J. Exp. Clin. Cancer Res. 43 (2024), 237.
[93]	Y Liu, B Qing, W Ke, et al., MEK inhibitor trametinib combined with PI3K/mTOR inhibitor BEZ-235 as an effective strategy against NSCLC through impairment of glucose metabolism, Cell. Signal. 124 (2024), 111415.
[94]	S. Wang, Z. Cheng, Y. Cui, et al., PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway, J. Transl. Med. 21 (2023), 819.
[95]	J.P. Couto, M. Vulin, C. Jehanno, et al., Nicotinamide N-methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer, EMBO J. 42 (2023), EMBJ2022112559.
[96]	P. Pissios, Nicotinamide N-methyltransferase: More than a vitamin B3 clearance enzyme, Trends Endocrinol. Metab. 28 (2017) 340-353.
[97]	E.M. Slominska, K. Kowalik, R.T. Smolenski, et al., Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure, Pediatr. Nephrol. 21 (2006) 800-806.
[98]	A Liu, X Zhu, W Sun, et al., Nicotinamide N-methyltransferase as a potential therapeutic target for neurodegenerative disorders: Mechanisms, challenges, and future directions, Exp. Neurol. 389 (2025), 115253.
[99]	A. Kannt, S. Rajagopal, S.V. Kadnur, et al., A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders, Sci. Rep. 8 (2018), 3660.
[100]	H. Neelakantan, H Wang, V. Vance, et al., Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase, J. Med. Chem. 60 (2017) 5015-5028.
[101]	W. He, Neurotrophic and antileukemic daphnane diterpenoids from Synaptolepis kirkii, Bioorg. Med. Chem. 10 (2002) 3245-3255.
[102]	Z Zhan, C Fan, J Ding, et al., Novel diterpenoids with potent inhibitory activity against endothelium cell HMEC and cytotoxic activities from a well-known TCM plant Daphne genkwa, Bioorg. Med. Chem. 13 (2005) 645-655.
[103]	G Li, B Kong, Q Tong, et al., Vanillin downregulates NNMT and attenuates NNMT-related resistance to 5-fluorouracil via ROS-induced cell apoptosis in colorectal cancer cells, Oncol. Rep. 45 (2021), 110.
[104]	J.Y. Hong, H.J. Chung, H.J. Lee, et al., Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa, J. Nat. Prod. 74 (2011) 2102-2108.
[105]	T. Frum, A. Ralston, Cell signaling and transcription factors regulating cell fate during formation of the mouse blastocyst, Trends Genet. 31 (2015) 402-410.
[106]	A.K. Brown, A.E. Webb, Regulation of FOXO factors in mammalian cells. Curr. Top. Dev. Biol. 127 (2018) 165-192.
[107]	G. Narendra, B. Raju, H. Verma, et al., Raloxifene and bazedoxifene as selective ALDH1A1 inhibitors to ameliorate cyclophosphamide resistance: A drug repurposing approach, Int. J. Biol. Macromol. 242 (2023), 124749.
[108]	A. He, Y. Pu, C. Jia, et al., The influence of exercise on cancer risk, the tumor microenvironment and the treatment of cancer, Phys. Med. 54 (2024) 1371-1397.
[109]	C Wei, X Li, Y Jin, et al., Does the liver facilitate aging-related cognitive impairment: Conversation between liver and brain during exercise J. Cell. Physiol. 239 (2024), e31287.
[110]	S. Ficarra, E. Thomas, A. Bianco, et al., Impact of exercise interventions on physical fitness in breast cancer patients and survivors: A systematic review, Breast Cancer 29 (2022) 402-418.
[111]	S. Rodriguez-Canamero, A.I. Cobo-Cuenca, J.M. Carmona-Torres, et al., Impact of physical exercise in advanced-stage cancer patients: Systematic review and meta-analysis, Cancer Med. 11 (2022) 3714-3727.
[112]	X Li, Y Zhang, X Ding, et al., Mass spectrometry chromatography-based metabolomics: The effect of long-term aerobic exercise on learning ability and the metabolism of intestinal contents in mice with Alzheimer’s disease, Metabolites 13 (2023), 1150.
[113]	H. Han, Y. Zhao, J. Du, et al., Exercise improves cognitive dysfunction and neuroinflammation in mice through Histone H3 lactylation in microglia, Immun. Ageing 20 (2023), 63.
[114]	G. Xu, P. Yu, Y. Hu, et al., Exercise training decreases lactylation and prevents myocardial ischemia-reperfusion injury by inhibiting YTHDF2, Basic Res. Cardiol. 119 (2024) 651-671.
[115]	Y Gao, N.I. Martin, M.J. van Haren, Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target, Drug Discov. Today 26 (2021) 2699-2706.